Barclays
SUPN icon

Barclays’s Supernus Pharmaceuticals SUPN Stock Holding History

Barclays’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-160,500
Closed -$3.81M – 6439
2019
Q4 		$3.81M Buy
160,500
+65,800
+69% +$1.6M ﹤0.01% 2305
2019
Q3 		$2.6M Buy
+94,700
New +$2.81M ﹤0.01% 2540
2018
Q3 		– Sell
-4,100
Closed -$245K – 7379
2018
Q2 		$245K Buy
+4,100
New +$212K ﹤0.01% 4549
2017
Q4 		– Sell
-700
Closed -$28K – 7101
2017
Q3 		$28K Buy
700
+500
+250% +$21.6K ﹤0.01% 5647
2017
Q2 		$9K Buy
+200
New +$7.12K ﹤0.01% 6089

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's SUPN Position: Q1 2026 in Review

Barclays reduced its Supernus Pharmaceuticals (SUPN) stake by 0.31% in Q1 2026, selling an estimated $17.5K and leaving 109,114 shares worth $5.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

Barclays first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $11M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Barclays held 109,114 shares of Supernus Pharmaceuticals worth $5.64M as of Q1 2026.
  • Barclays sold 343 Supernus Pharmaceuticals shares in Q1 2026, an estimated $17.5K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1744 holding.
  • Barclays first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Supernus Pharmaceuticals position peaked at $11M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.